Spineway Reports 4% Revenue Growth for 2025

On February 17, 2026, Spineway announced its financial results for 2025, showing a 4% increase in revenue, reaching €12.4 million despite challenges in Latin America and Asia. The company improved its gross margin to €8.6 million, which is 69.6% of its revenue, showing a slight year-on-year improvement.

The net operating expenses rose by 5% according to pro forma data, reflecting ongoing regulatory costs. The operating loss was stable at €2.1 million. Spineway's financial structure remains solid, with reduced net financial expenses and research tax credits normalizing. Although the company ended the year with a €2.2 million net loss, this marks a €1.6 million improvement from the previous year.

Spineway's ongoing investments in regulatory affairs and R&D are bolstering its growth potential, supported by synergies from past acquisitions. The company's ambition to enhance its position in the spinal surgery market appears on track.